T

TransMedics

Ex-vivo organ perfusion platform

Head of Pharmacy Operations

Full-TimeUpdated on 10/23/2026
$159.9k - $227.6k+ Bonus + Equity
Expert
PharmD, Bachelor of Science (BS)
Andover, MA, USA
In PersonRequires approximately 25% travel to clinical hubs and headquarters. Headquarters relocation to Somerville, MA is planned by 2028.
Medical, Clinical & VeterinaryPharmacy

About the job

Requirements
  • A PharmD or Bachelor of Science in Pharmacy from an ACPE-accredited program is required.
  • An active, unrestricted U.S. pharmacist license in at least one state is required, along with willingness to obtain additional state licenses within the first 12 months.
  • At least 8 years of pharmacy practice experience, including at least 3 years as Pharmacist-in-Charge or equivalent in specialty, mail-order, central-fill, wholesale distribution, 3PL, or health-system operations, is required.
  • Hands-on experience with multistate licensure, board of pharmacy inspections, and DEA compliance for Schedule II–V products is required.
  • Working knowledge of DSCSA, cold-chain and USP <659>/<1079> storage and distribution standards, and NABP drug distributor accreditation is required.
  • A track record authoring SOPs, leading audits or inspections, and managing CAPA in a regulated environment is required.
  • The role requires communicating with non-pharmacist executives and representing the company with regulators.
  • Willingness to travel approximately 25% to clinical hubs and headquarters is required.
Responsibilities
  • Serve as Pharmacist-in-Charge, Designated Representative, or Responsible Person for the company's main and clinical hub pharmacies, wholesale distributor, and 3PL licenses.
  • Own multistate licensing for resident and non-resident pharmacy, wholesale distributor, 3PL, and controlled-substance registrations for every clinical hub and ship-to state, including renewals, changes of ownership, and inspection follow-up.
  • Lead NABP, drug distributor accreditation, and state board inspection readiness, and serve as the primary company contact during inspections and audits.
  • Partner with Supply Chain to establish remote controlled pharmaceutical and solution dispensing systems across clinical hubs to maintain quality control and tracking.
  • Define and maintain SOPs for receipt, verification, storage, pick/pack, dispensing, shipping, returns, recalls, and destruction of prescription drugs at every hub.
  • Set cold-chain and environmental-monitoring standards for temperature-sensitive and specialty products, including excursion evaluation and product disposition.
  • Set controlled-substance standards to DEA requirements, covering CSOS ordering, receipt, secure storage, inventory reconciliation, suspicious-order monitoring, theft/loss reporting, and reverse distribution.
  • Drive network-wide DSCSA compliance, including serialization, transaction data, trading-partner verification, and suspect or illegitimate product investigations.
  • Assess each hub on-site on a regular cadence and address deficiencies through successful closure.
  • Build and run the pharmacy compliance program, including risk assessments, monitoring, internal audits, deviations, and CAPAs, with reporting to executive leadership and the board-level compliance committee.
  • Partner with Quality and Regulatory Affairs to align pharmacy SOPs with the company QMS, including 21 CFR Part 820 and ISO 13485 for device operations and applicable cGDP expectations for drug distribution.
  • Track evolving federal and state pharmacy, wholesale, and controlled-substance regulations and translate them into operational requirements and training.
  • Lead pharmacy-related investigations, recalls, and field actions with Quality, Legal, and manufacturers.
  • Act as pharmacy subject-matter expert for new hub openings, product development and launches (including drug-device combination products), payer and manufacturer contracting, and technology selection for pharmacy management, inventory, serialization, and temperature monitoring.
  • Build and deliver pharmacy training and competency programs for hub technicians and warehouse staff.
  • Represent the company with state boards, NABP, trade associations, manufacturers, and key customers on pharmacy practice matters.
  • Mentor pharmacists and technicians across the network and shape the future pharmacy organization as it scales.
Desired Qualifications
  • Experience in a medical device or drug-device combination product company, or within an FDA-registered QMS, is preferred.
  • Experience opening or licensing new pharmacy or distribution sites from greenfield is preferred.
  • Familiarity with 340B, specialty pharmacy accreditation (URAC, ACHC), or manufacturer limited-distribution networks is preferred.
  • Board certification (BCPS, BCSCP) or credentials in regulatory affairs or quality (RAC, CQA) are preferred.
  • Experience selecting or implementing pharmacy management, serialization, or environmental-monitoring systems is preferred.

About the company

TransMedics makes the Organ Care System (OCS), a portable platform that keeps donor organs alive outside the body by warm, oxygenated perfusion and continuous viability monitoring. The OCS circulates warmed, nutrient-rich blood through the organ, allowing surgeons to assess health in near-physiological conditions. Revenue comes from selling OCS consoles, disposable sets used per procedure, and the National OCS Program, which provides end-to-end organ retrieval and logistics services. It distinguishes itself by holding FDA approvals to preserve and assess hearts, lungs, and livers in the United States and by integrating hardware, consumables, and logistics to expand transplant opportunities.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Andover, Massachusetts

Founded

1998

Get referred to TransMedics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 21% to $189.9 million, and guidance increased to $737-$757 million.
  • FDA approved ENHANCE Heart and DENOVO Lung IDEs in January-February 2026, advancing next-generation trials.
  • PAD Aviation closed July 6, 2026, opening pan-European transplant logistics contracts.

What critics are saying

  • Judge Sorokin partially denied dismissal July 21, 2026, forcing discovery in the fraud case.
  • CHOPS and kidney development burn cash while gross margin slipped to 60% in Q2 2026.
  • A bad ENHANCE or DENOVO safety signal in 2026-2027 would damage OCS credibility.

What makes TransMedics unique

  • FDA-approved OCS remains the only U.S. warm-perfusion platform for hearts, lungs, and livers.
  • The National OCS Program bundles surgeons, logistics, aircraft, and disposables into a sticky ecosystem.
  • PAD Aviation extends TransMedics' logistics moat into Europe, copying the U.S. NOP playbook.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Short Term Disability
  • Long Term Disability
  • Health Savings Account/Flexible Spending Account
  • Dependent Care Flexible Spending Account
  • 401(k) Plan
  • Pet insurance
  • Employee Stock Purchase Plan
  • Wellness Program

Growth & Insights and Company News

6 month growth

1%

1 year growth

1%

2 year growth

2%
Yahoo Finance
Oct 1st, 2026
TransMedics director buys $109K in stock amid 30% yearly decline

David Weill, a director at TransMedics Group, purchased 1,336 shares of common stock for approximately $109,000 on 11 September 2026, according to an SEC Form 4 filing. The purchase increased his direct holdings by 9% to 16,392 shares, valued at roughly $1.4 million. The transaction occurred as the stock recorded a one-year return of -30%. TransMedics, a commercial-stage medical technology company with a market capitalisation of $2.7 billion, develops the Organ Care System, a portable device that preserves and monitors donor organs for transplantation. The company reported trailing twelve-month revenues of $668.5 million and net income of $151.7 million. Management has guided for 22%-25% sales growth in 2026 as it expands internationally and develops new platforms.

Yahoo Finance
Sep 15th, 2026
TransMedics and SoFi stocks fall 28% and 34% but show strong buying potential

TransMedics Group and SoFi Technologies have declined 28% and 34% respectively over the past year, presenting potential buying opportunities despite broader market strength driven by tech giants. TransMedics, which developed the Organ Care System for transplants, faces near-term headwinds. Second-quarter revenue grew 21% year over year to $189.9 million, marking a slowdown from recent quarters. Adjusted earnings per share fell 52% to $0.44. However, the company is investing in expansion initiatives, including potential kidney transplant approval and a logistics network for greater control over the organ transplant cycle. These investments are pressuring current profits but could drive future growth. The OCS technology maintains organ temperature and blood supply during transport, addressing limitations of traditional cold storage methods. With a large addressable market remaining, the stock may offer value at current levels.

PR Newswire
Aug 4th, 2026
TransMedics reports 21% revenue growth to $190M in Q2 2026, raises guidance despite margin pressure

TransMedics Group reported second quarter 2026 revenue of $189.9 million, a 21% increase from $157.4 million in the prior year period. The growth was driven primarily by increased utilisation of the company's Organ Care System, particularly in liver and heart transplants through its National OCS Programme, as well as logistics services revenue. Gross margin decreased to 60% from 61% year-over-year, reflecting a higher mix of service revenue and temporary product-cost factors. Net income fell to $14.7 million, or $0.41 per diluted share, compared to $34.9 million, or $0.92 per share, in the second quarter of 2025. The company raised the low end of its full-year 2026 revenue guidance to a range of $737 million to $757 million, representing approximately 22% to 25% growth. TransMedics develops portable extracorporeal warm perfusion technology for donor organ transplantation.

MarketScreener
Jul 6th, 2026
TransMedics invests in PAD Aviation to build Europe-wide organ transplant air logistics network

TransMedics Group has completed a strategic investment in PAD Aviation service GmbH, a Germany-based private aviation operator. The deal aims to establish a dedicated organ transplantation air logistics network across Europe, replicating TransMedics' OCS NOP model from the US. PAD Aviation, founded in 2006, operates from a 24/7 hub in Paderborn, Germany. The company maintains a fleet of nine Embraer Phenom 300 aircraft and employs over 40 pilots, holding a valid EASA Air Operator Certificate. TransMedics develops portable extracorporeal warm perfusion technology for preserving and assessing donor organs. The investment supports the company's efforts to expand adoption of its OCS perfusion technology and create a pan-European organ transport logistics network across the European Union.

Yahoo Finance
Jul 2nd, 2026
TD Cowen sets $120 target on TransMedics, sees 77% upside on transplant growth

TransMedics Group has received a 'Buy' rating from TD Cowen with a $120 price target, implying 77% upside from its last close. The firm cited growing US transplant activity in heart, liver and lung procedures as a key driver for the company's Organ Care System technology and logistics business. Monthly US transplant data showed volumes rose approximately 5% year-over-year in the second quarter of 2026. TransMedics generated $173.9 million in total revenue in the first quarter of 2026, up 21% year-over-year, with product revenue reaching $108 million and service revenue contributing $66 million. The company ended the quarter with $461.7 million in cash and cash equivalents. Shares closed up 2% on Wednesday and gained further in after-hours trading.